chain pair that specifically binds a tumor antigen, wherein said variable domain is from an antibody ~~is~~ produced by hybridoma clone: 1D5 (PTA-5958), 2E1 (PTA-5961~~5691~~), 2H9 (PTA-5962), 2D11 (PTA-5960), or 1F2 (PTA-5959), or is from a chimeric, humanized or human antibody variant of said antibody.

19. Use of a therapeutically effective amount of said antibody or a fragment thereof of claim 1 or 2 for the manufacture of a medicament for treating cancer.

20. The use of claim 19, wherein said antibody is a monoclonal antibody.

21. The use of claim 19, wherein said antibody is humanized, human or chimeric.

22. The use of claim 19, wherein said cancer is breast, ovarian, prostate, cervical or pancreatic cancer.

23. The use of claim 19, wherein said medicament is suitable for administration with one or more additional cancer therapies.

24. The use of claim 23, wherein said additional cancer therapy is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, hormonal therapy, or surgery.

25. The use of claim 19 wherein said medicament is suitable for administration at a dose such that said antibody does not detectably bind to neutrophils.

26. Use of a therapeutically effective amount of said antibody or fragment thereof of claim 1 or 2 for the manufacture of a medicament for treating or ameliorating a B-cell malignancy.

27. The use of claim 26, wherein said B-cell malignancy is a B-cell lymphocytic leukemia or non-Hodgkin's lymphoma.

28. The use of claim 26, wherein said antibody or fragment is conjugated to a therapeutic agent or drug.